Non-Hodgkin's lymphomas-current status of therapy and future perspectives

European Journal of Cancer

Volumn 31, Issue 13-14, 1995, Pages 2141-2145

  Hiddemann, W ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

bone marrow transplantation; non Hodgkin's lymphoma; peripheral stem cell transplantation; prognostic factors; purine analogues; R.E.A.L. classification

Indexed keywords

ALPHA INTERFERON; CLADRIBINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; HYDROXYDAUNORUBICIN; MITOXANTRONE; PENTOSTATIN; PREDNIMUSTINE; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE;

BONE MARROW TRANSPLANTATION; CANCER THERAPY; FUTUROLOGY; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STEM CELL TRANSPLANTATION;

HUMANS; LYMPHOMA, NON-HODGKIN; PALLIATIVE CARE; RISK FACTORS; TREATMENT OUTCOME;

EID: 0029612174     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00367-3     Document Type: Review

References (68)

1. Updated Kiel classification for lymphomas
2. The Non-Hodgkin's Lymphoma Pathologic Classification Project National Cancer Institute sponsored study of classification of non- Hodgkin's lymphomas Summary and description of a working formulation for clinical usage
3. A proposal for an international consensus on the classification of lymphoid neoplasms
4. Strategien der Behandlung von Non-Hodgkin Lymphomen
5. Treatment of non-Hodgkin's lymphoma
6. Low-grade lymphoma 1993: state of the art
7. Current status and future perspectives in the treatment of low-grade non-Hodgkin's lymphomas
8. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD
9. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma
10. Predictive model for prognosis in advanced diffuse histiocytic lymphoma
11. A new serologic staging system for large-cell lymphomas based on initial β2-microglobulin and lactate dehydrogenase levels
12. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy; The Groupe d'Études des Lymphomes Agressifs
13. Klinisch relevante Prognosefaktoren maligner Lymphome
14. HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma
15. Beta-2-microglobulin (β2M) and HLA-DR cellular expression in relapsing large cell lymphomas (LCL): relationship to survival and serum β2M levels
16. Development of a predictive model for aggressive lymphoma: the International non-Hodgkin's lymphoma prognostic factors project
17. Is the international prognostic index for aggressive lymphoma patients useful for follicular lymphoma patients?
18. Applicability of the international index for aggressive lymphomas to patients with low-grade lymphomas
19. Independent prognostic significance of nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67
20. Association of DNA content and proliferative activity with clinical outcome in patients with diffuse mixed cell and large cell non-Hodgkin's lymphoma
21. Survival of patients with localized diffuse histiocytic lymphoma
22. Brief chemotherapy and involved field radiation therapy for limited-stage histologically aggressive lymphoma
23. Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy
24. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy
25. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphoma
26. Hydroxydaunomycin (adriamycin) combination chemotherapy in malignant lymphoma
27. Comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma
28. Randomized, double-blind, placebo-controlled phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas
29. Granulocyte colony stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma. A randomized controlled trial
30. Haemopoietic growth factors and dose intensity in high-grade and intermediate grade lymphoma
31. Prospective phase III study of autologous bone marrow transplantation (ABMT) vs. short intensive chemotherapy (IC) vs. allogeneic bone marrow transplantation (Allo-BMT) during first complete remission (CR) of acute myelogenous leukemia (AML). Results of the EORTC-GIMEMA AML 8A trial
32. Comparison of autologous bone marrow transplantation (ABMT) with sequential chemotherapy for aggressive non-Hodgkin's lymphoma (NHL) in first complete remission: a study on 464 patients (LNH87 protocol)
33. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma
34. High-dose cyclophosphamide etoposide and BCNU with non-cryopreserved autologous bone marrow transplantation for poor prognosis malignant lymphoma
35. Role of radiation therapy in localized non-Hodgkin's lymphoma
36. Management of localized non-Hodgkin's lymphoma: the experience at St Bartholomew's Hospital 1972–1985
37. Stage I–II low grade non-Hodgkin's lymphoma: prognostic factors and treatment results
38. Non-Hodgkin lymphomas (NHL)—early stage interim results of a multicentre trial
39. Stage I–II low-grade lymphomas a prospective trial of combination chemotherapy and radiotherapy
40. A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas
41. Adjuvant cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study
42. Clinical features and prognosis of follicular large-cell lymphoma: a report from Nebraska Lymphoma study group
43. Treatment approaches to the low-grade lymphomas
44. Management of follicular lymphoma
45. Novantrone in combination with sterecyte (NOSTE) in treatment of unfavourable non-Hodgkin's lymphoma
46. Prednimustine, mitoxantrone (PmM) versus cyclophosphamide, vincristine, prednisone (COP) for the treatment of the advanced low grade non-Hodgkin's lymphoma
47. The treatment of indolent lymphomas: watchful waiting v. aggressive combined modality treatment
48. What's the deal with follicular lymphomas?
49. Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden
50. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemo-immunotherapy
51. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma
52. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma
53. Randomized study of chlorambucil (CB) compared to interferon (alfa- 2b) combined with CB in low-grade non-Hodgkin's lymphoma an interim report of a randomized study
54. Interferon 2b in the treatment of follicular lymphoma: preliminary results of a trial in progress
55. Cyclophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low grade lymphomas: a preliminary report of an intergroup trial (CALGB 8691 and EST 7486)
56. Maintenance of remission with human recombinant alpha-2 interferon (Roferon-A) in patients with stages III and IV low grade malignant non-Hodgkin's lymphoma. Results from a prospective, randomised phase III clinical trial in 331 patients
57. New aspects in the treatment of advanced low-grade non-Hodgkin's lymphomas prednimustine/mitoxantrone (PmM) vs cyclophosphamide/vincristine/prednisone (COP) followed by interferon vs observation only— a preliminary update of the German Low Grade Lymphoma Study Group
58. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation
59. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse
60. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma
61. Purine analogs in the treatment of lowgrade lymphomas and chronic lymphocytic leukemias
62. Fludarabine in the management of malignant lymphomas
63. New antimetabolites in the treatment of human malignancies
64. The newer purine analogs
65. Phase I study of the combination of fludarabine, mitoxantrone and dexamethasone in low-grade lymphoma
66. 131I anti-B1 (anti-CD20) antibody
67. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support